BiVictriX's Novel Panel of Cancer-Restricted
 Antigen Combinations 
Bi-Cygni
Generation of leads with improved potency and selectivity

®

Lead Optimization
in to Multiple Therapeutic Modalities
BiVictriX links Bi-Cygni   to expertise in the design, discovery and development of Antibody Drug Conjugates (ADCs).